7 March 2024 11:00 GMT

Notice of Annual General Meeting

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2024 and Shareholders' Circular (the Notice).

The Company's Annual General Meeting (AGM) will be digitally-enabled and will be held on Thursday 11 April at 14:30 (BST). Full details and joining instructions are set out in the Notice. 

The Notice, proxy form and 2020 Performance Share Plan have been submitted to the National Storage Mechanism and will shortly be available for inspection athttps://data.fca.org.uk/#/nsm/nationalstoragemechanism. The Notice is also available on the Company's website atwww.astrazeneca.com/noticeofmeeting2024.

The Notice is being despatched to shareholders today.

The business to be conducted at the AGM is summarised below:

1.   To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023

2.   To confirm the 2023 interim dividends

3.   To re-appoint PricewaterhouseCoopers LLP as Auditor

4.   To authorise the Directors to agree the remuneration of the Auditor

5.   To elect or re-elect Directors

6.   To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2023

7.   To approve the Directors' Remuneration Policy

8.   To approve amendments to the AstraZeneca Performance Share Plan 2020

9.   To authorise limited political donations

10. To authorise the Directors to allot shares

11. To authorise the Directors to disapply pre-emption rights

12. To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

13. To authorise the Company to purchase its own shares

14. To reduce the notice period for general meetings

Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, only holders of ordinary shares entered in the register of members of the Company by 6.30pm (BST) on 9 April 2024 (or their duly appointed proxies), or if this meeting is adjourned, in the register of members by 6.30pm (BST) two days prior to any adjourned meeting, are entitled to attend or vote at the AGM in respect of the number of ordinary shares registered in their name at that time. Changes to the entries in the register of members after 6.30pm (BST) on 9 April 2024, or if this meeting is adjourned, in the register of members after 6.30pm (BST) two days prior to any adjourned meeting, shall be disregarded in determining the rights of any person to attend or vote at the AGM. The Record Date applied to the Euroclear Sweden system to determine entitlement to participate and vote at the AGM is close of business on 2 April 2024.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca).

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).

Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com orvisit www.rns.com.